Ozcan T, Turan C, Ekici E, Gökmen O, Doğan M, Kaleli B, Uludağ H, Karayalçin R
Labor and High-Risk Pregnancy Department, Dr. Zekai Tahir Burak Maternity Hospital, Ankara, Turkey.
Gynecol Obstet Invest. 1995;39(1):60-2. doi: 10.1159/000292378.
Betamimetic drugs are commonly used for tocolytic therapy. To determine their potential role in periventricular-intraventricular neonatal hemorrhage (IVH), 103 preterm births with cranial ultrasonography results were evaluated for the history of betamimetic therapy. The study group was divided into three subgroups according to the cause of the preterm delivery: 44 patients were accepted as tocolysis failure (group A); 53 patients were too late for tocolysis (group B), and these latter cases were taken as controls for group A; for the remaining 6 patients, tocolysis was contraindicated due to fetomaternal reasons (group C), and these cases were not included in the analysis. In group A, 32 patients got ritodrine, 6 patients got combined therapy including ritodrine plus magnesium sulfate or nifedipine. When cases in group A who got ritodrine only or combined therapy are compared with the no-treatment group, no significant difference in neonatal IVH incidences could be found (p > 0.005). Ritodrine does not appear to affect the incidence of neonatal IVH.
β-拟交感神经药物常用于保胎治疗。为确定其在脑室周围-脑室内新生儿出血（IVH）中的潜在作用，对103例有头颅超声检查结果的早产病例进行了β-拟交感神经药物治疗史评估。研究组根据早产原因分为三个亚组：44例患者被视为保胎治疗失败（A组）；53例患者因保胎治疗时机过晚（B组），后一组病例作为A组的对照；其余6例患者因母婴原因保胎治疗禁忌（C组），这些病例未纳入分析。在A组中，32例患者使用利托君，6例患者接受包括利托君加硫酸镁或硝苯地平的联合治疗。将A组中仅使用利托君或联合治疗的病例与未治疗组进行比较时，未发现新生儿IVH发生率有显著差异（p>0.005）。利托君似乎不影响新生儿IVH的发生率。
